M&A Deal Summary

Roche Acquires Genentech

On March 12, 2009, Roche acquired life science company Genentech for 46.8B USD

Acquisition Highlights
  • This is Roche’s 7th transaction in the Life Science sector.
  • This is Roche’s largest (disclosed) transaction.
  • This is Roche’s 5th transaction in the United States.
  • This is Roche’s 1st transaction in California.

M&A Deal Summary

Date 2009-03-12
Target Genentech
Sector Life Science
Buyer(s) Roche
Deal Type Merger
Deal Value 46.8B USD

Target

Genentech

San Francisco, California, United States
website
Genentech is a biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious or life-threatening medical conditions. The Company is based in San Francisco.

Search 190,567 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Roche

Basel, Switzerland

website


Category Company
Founded 1896
Sector Life Science
Employees100,920
Revenue 63.3B CHF (2022)
DESCRIPTION
Roche's corporate headquarters in Basel, Switzerland.
Roche's corporate headquarters in Basel, Switzerland.

Roche is a research-focused healthcare company focused on pharmaceuticals and diagnostics. Roche offers differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche was founded in 1896 and is based in Basel, Switzerland.


DEAL STATS #
Overall 10 of 42
Sector (Life Science) 7 of 29
Type (Merger) 1 of 4
State (California) 1 of 14
Country (United States) 5 of 28
Year (2009) 1 of 2
Size (of disclosed) 1 of 29
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2008-07-23 ARIUS Research

Toronto, Ontario, Canada

ARIUS Research, Inc. is a biotechnology company discovering and developing the next wave of antibody therapeutics to treat cancer and other diseases. At the core of the Company is a unique, proprietary FunctionFIRST technology platform that generates and selects therapeutic antibodies based on their activity. This antibody generation engine has enabled ARIUS to develop a pipeline of more than 400 antibody drug candidates.

Buy CA$191M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2009-03-16 Innovatis AG

Bielefeld, Germany

Innovatis AG develops, produces and distributes fully automated cell analysis equipment (bioprocess analysis). The systems overcome the drawbacks of manual analysis such as the high amounts of time and work involved, the restricted data that is acquired and the high margin of error.

Buy €15M